Iacta aims to bring the latest technology to the healthcare industry and eyecare markets. With our vast partnerships and connections, we can identify new technologies and launch them successfully.
IACTA Pharmaceuticals was established to develop and commercialize innovative eyecare products. We’re dedicated to treating diseases, advancing technology and improving patient outcomes.
Our lead investigational product, NM133, is a nano-enabled form of cyclosporine A which is being developed for the treatment of dry eye using licensed proprietary Molecular Envelope Technology (MET).